Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
Part of Cancer, Skin clinical trials.
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be a solid tumor that has spread or can't be removed with surgery, and standard treatments have stopped working or aren't right for you.
- Your tumor needs to have a specific genetic change in the RAS/MAPK pathway (like an NRAS, KRAS, or BRAF mutation) — the study will check this.
- You need to be in generally good health (able to do daily activities with little or no help) and have adequate organ function.
- You cannot have taken certain targeted drugs (MEK or BRAF inhibitors) before joining, and you cannot have untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.